bioAffinity Technologies (BIAF) Cash & Equivalents (2021 - 2026)

bioAffinity Technologies (BIAF) has 6 years of Cash & Equivalents data on file, last reported at $3.1 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $3.1 million, up 675.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.1 million (up 675.0% YoY), and the FY2025 annual result was $6.4 million, up 483.54% from the prior year.
• Cash & Equivalents slipped to $3.1 million in Q1 2026 per BIAF's latest filing, from $6.4 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $13.5 million in Q3 2022 and troughed at $400000.0 in Q1 2025.
• A 5-year average of $4.9 million and a median of $3.1 million in 2026 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents plunged 90.36% in 2024, then jumped 858.65% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $11.4 million in 2022, then plunged by 75.28% to $2.8 million in 2023, then plunged by 60.83% to $1.1 million in 2024, then surged by 483.54% to $6.4 million in 2025, then sank by 51.94% to $3.1 million in 2026.
• Business Quant data shows BIAF's Cash & Equivalents at $3.1 million in Q1 2026, $6.4 million in Q4 2025, and $7.7 million in Q3 2025.